Rigel To Present Phase 2 Results for Fostamatinib in Autoimmune Hemolytic Anemia at EHA Jun 12, 2018 7:30am EDT
Rigel Announces Availability of TAVALISSE™ (fostamatinib disodium hexahydrate) in the U.S. May 29, 2018 7:30am EDT
Rigel Announces First Quarter 2018 Financial Results and Provides Company Update May 01, 2018 4:01pm EDT
TAVALISSE™ (fostamatinib disodium hexahydrate) Phase 3 Data Published in the American Journal of Hematology Describes Pivotal Data and Overall Response Rate Versus Placebo Apr 30, 2018 7:30am EDT
Rigel Announces Conference Call and Webcast to Report First Quarter 2018 Financial Results Apr 24, 2018 7:30am EDT
